See the published version of this preprint at Chinese Medicine.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Jianxia Wen
Chengdu University of Traditional Chinese Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0002-1184-8758
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The combination of Aconiti Lateralis Radix Praeparata (ALRP) and Zingiberis Rhizoma (ZR) is one of the most typical representatives reflecting the very essence of the theory of Chinese material medica compatibility, which has been used to treat cardiovascular disease for many years. Previously, we demonstrated that ALRP-ZR prevented doxorubicin (DOX)-induced chronic heart failure (CHF) in vivo. However, its active components are still unclear. This study was aimed to investigate the therapeutic effect and potential mechanism of higenamine combined with [6]-gingerol (HG/[6]-GR) against doxorubicin (DOX) - induced chronic heart failure (CHF) in rats. Therapeutic effects of HG/[6]-GR on hemodynamics indices, serum biochemical indicators, histopathology and TUNEL staining of rats were assessed. Moreover, a UHPLC-Q-TOF/MS-based serum metabonomic approach coupled with biochemical assay has been performed to identify the potential mechanisms of HG/[6]-GR on DOX-induced CHF. HG/[6]-GR had effects on promoting of hemodynamic indices, decreasing serum biochemical indicators, and alleviating histological damage of heart tissue. Serum metabonomics analyses indicated that the therapeutic effects of HG and [6]-GR were mainly associated with the regulation of eight metabolites and twelve pathways, which may be responsible for the therapeutic efficacy of HG/[6]-GR. Moreover, the results showed that HG/[6]-GR could substantially regulate the expression level of energy metabolism-related metabolites and pathways. Multivariate statistical analysis has provided new insights for understanding CHF and investigating the therapeutic effects and mechanisms of HG/[6]-GR, which influencing the metabolites related to energy metabolism pathway.
Keywords
Higenamine, [6]-gingerol, metabolomics, chronic heart failure, energy metabolism, doxorubicin
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Chinese Medicine.
No community comments so far
Editorial decision: Accept
On 08 Nov, 2020
Editor assigned
On 22 Oct, 2020
Submission checks complete
On 21 Oct, 2020
Editor invited
On 21 Oct, 2020
Version 2
Posted 06 Oct, 2020
No comments provided
Review #2 received
Received 07 Oct, 2020
Reviewer #2 agreed
On 05 Oct, 2020
Reviewers invited
Invitations sent on 27 Sep, 2020
Reviewer #1 agreed
On 27 Sep, 2020
Review #1 received
Received 27 Sep, 2020
Editor assigned
On 25 Sep, 2020
Submission checks complete
On 24 Sep, 2020
Editor invited
On 24 Sep, 2020
No comments provided
Editorial decision: Minor revision
On 16 Sep, 2020
Review #2 received
Received 23 Aug, 2020
Reviewer #2 agreed
On 16 Aug, 2020
Review #1 received
Received 15 Jun, 2020
Reviewer #1 agreed
On 12 Jun, 2020
Reviewers invited
Invitations sent on 02 Jun, 2020
Editor assigned
On 26 May, 2020
First submitted
On 25 May, 2020
Submission checks complete
On 25 May, 2020
Editor invited
On 25 May, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Internal Medicine
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Chinese Medicine.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Jianxia Wen
Chengdu University of Traditional Chinese Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0002-1184-8758
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Chinese Medicine.
No community comments so far
Editorial decision: Accept
On 08 Nov, 2020
Editor assigned
On 22 Oct, 2020
Submission checks complete
On 21 Oct, 2020
Editor invited
On 21 Oct, 2020
Version 2
Posted 06 Oct, 2020
No comments provided
Review #2 received
Received 07 Oct, 2020
Reviewer #2 agreed
On 05 Oct, 2020
Reviewers invited
Invitations sent on 27 Sep, 2020
Reviewer #1 agreed
On 27 Sep, 2020
Review #1 received
Received 27 Sep, 2020
Editor assigned
On 25 Sep, 2020
Submission checks complete
On 24 Sep, 2020
Editor invited
On 24 Sep, 2020
No comments provided
Editorial decision: Minor revision
On 16 Sep, 2020
Review #2 received
Received 23 Aug, 2020
Reviewer #2 agreed
On 16 Aug, 2020
Review #1 received
Received 15 Jun, 2020
Reviewer #1 agreed
On 12 Jun, 2020
Reviewers invited
Invitations sent on 02 Jun, 2020
Editor assigned
On 26 May, 2020
First submitted
On 25 May, 2020
Submission checks complete
On 25 May, 2020
Editor invited
On 25 May, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Internal Medicine
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Chinese Medicine.
The combination of Aconiti Lateralis Radix Praeparata (ALRP) and Zingiberis Rhizoma (ZR) is one of the most typical representatives reflecting the very essence of the theory of Chinese material medica compatibility, which has been used to treat cardiovascular disease for many years. Previously, we demonstrated that ALRP-ZR prevented doxorubicin (DOX)-induced chronic heart failure (CHF) in vivo. However, its active components are still unclear. This study was aimed to investigate the therapeutic effect and potential mechanism of higenamine combined with [6]-gingerol (HG/[6]-GR) against doxorubicin (DOX) - induced chronic heart failure (CHF) in rats. Therapeutic effects of HG/[6]-GR on hemodynamics indices, serum biochemical indicators, histopathology and TUNEL staining of rats were assessed. Moreover, a UHPLC-Q-TOF/MS-based serum metabonomic approach coupled with biochemical assay has been performed to identify the potential mechanisms of HG/[6]-GR on DOX-induced CHF. HG/[6]-GR had effects on promoting of hemodynamic indices, decreasing serum biochemical indicators, and alleviating histological damage of heart tissue. Serum metabonomics analyses indicated that the therapeutic effects of HG and [6]-GR were mainly associated with the regulation of eight metabolites and twelve pathways, which may be responsible for the therapeutic efficacy of HG/[6]-GR. Moreover, the results showed that HG/[6]-GR could substantially regulate the expression level of energy metabolism-related metabolites and pathways. Multivariate statistical analysis has provided new insights for understanding CHF and investigating the therapeutic effects and mechanisms of HG/[6]-GR, which influencing the metabolites related to energy metabolism pathway.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Loading...